Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) frequently develops resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.
• Aberrant c-Met activity is implicated in 5-20% of EGFR TKI-resistant NSCLC cases, establishing a rationale for targeting c-Met.
• EGFR TKI-resistant tumors often retain sensitivity to EGFR signaling, indicating potential synergy with combined c-Met and EGFR inhibition.

Purpose of the Study:

• To evaluate the role of c-Met inhibitors in EGFR TKI-resistant NSCLC.
• To assess the efficacy of selective c-Met inhibitors, such as capmatinib and tepotinib, in this patient population.
• To consider factors influencing the success of future clinical trials for c-Met inhibitors in resistant NSCLC.

Main Methods:

• Review of phase III trials (onartuzumab, tivantinib) and phase Ib/II trials (capmatinib, tepotinib).
• Analysis of c-Met activity as a resistance mechanism in NSCLC.
• Consideration of selective versus non-selective c-Met inhibitors and their properties.

Main Results:

• Previous c-Met inhibitors (onartuzumab, tivantinib) showed limited benefit, partly due to trial design excluding resistant populations.
• Selective c-Met TKIs (capmatinib, tepotinib) demonstrate promising efficacy in early-phase trials.
• Selective c-Met TKIs target both HGF-dependent and -independent c-Met activity with potentially lower toxicity.

Conclusions:

• C-Met remains a rational target in EGFR TKI-resistant NSCLC, particularly with selective inhibitors.
• Combined inhibition strategies, including continued EGFR TKI therapy, warrant further investigation.
• Optimizing patient selection and therapeutic strategies is crucial for future clinical trial success in c-Met-positive, EGFR TKI-resistant NSCLC.